The Albus Program is an annual international award focused on innovative ideas related to albumin and its role as a therapeutic product. Proposals may include, but are not limited to: efficacy, mechanism of action, safety and tolerability, quality of life and pharmacoeconomics.

The Program offers 1 award of €50,000 to applicants whose proposals best match the program’s objectives, as assessed by an independent review committee. Albus aims to:

  • Develop novel concepts on albumin research.
  • Encourage discovery of beneficial albumin applications.
  • Further investigate mechanisms of action or clinical effects in different indications.